Sanders Morris Harris LLC Purchases New Shares in Amgen Inc. $AMGN

Sanders Morris Harris LLC purchased a new position in Amgen Inc. (NASDAQ:AMGN) during the third quarter, Holdings Channel reports. The institutional investor purchased 4,292 shares of the medical research company’s stock, valued at approximately $1,809,000.

A number of other institutional investors also recently modified their holdings of the company. BlackRock Inc. increased its position in shares of Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after buying an additional 2,261,544 shares during the period. State Street Corp lifted its holdings in Amgen by 38.2% in the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after buying an additional 11,656,755 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Amgen by 12.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock valued at $1,952,156,000 after buying an additional 605,928 shares during the period. Bank of America Corp DE acquired a new position in Amgen in the second quarter valued at $1,831,903,000. Finally, Invesco Ltd. boosted its position in Amgen by 7.2% during the fourth quarter. Invesco Ltd. now owns 4,788,460 shares of the medical research company’s stock valued at $1,567,311,000 after acquiring an additional 321,173 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on AMGN shares. Oppenheimer reiterated an “outperform” rating on shares of Amgen in a report on Wednesday, September 23rd. Scotiabank lifted their price objective on Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a research report on Monday, September 28th. Argus boosted their price objective on Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. Cantor Fitzgerald boosted their price objective on Amgen from $400.00 to $440.00 and gave the company a “neutral” rating in a research note on Monday, October 5th. Finally, Wells Fargo & Company lowered their target price on Amgen from $435.00 to $430.00 and set an “equal weight” rating for the company in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $387.93.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Promising Tezspire trial results: Amgen and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis. Nearly 70% of patients receiving the higher dose achieved remission at week 24, potentially expanding the drug’s addressable market in a condition with limited treatment options. What Could Amgen 70% Remission Trial Result Mean For Its Pipeline?
• Positive Sentiment: UBS raised its price target to $470, signaling additional upside and reinforcing optimism about Amgen’s pipeline and earnings outlook. Cantor Fitzgerald also recently lifted its target to $440. UBS Raises Target for Amgen Stock
• Positive Sentiment: Pipeline and regulatory momentum remain supportive. Investors are focused on the obesity candidate MariTide, with three Phase 3 diabetes studies expected to begin in 2026, as well as the recent European authorization for Jascayd. Erste Group also raised its FY2027 EPS estimate to $24.66 from $24.36, above the current-year consensus of $22.94.
• Neutral Sentiment: Evenity development continues: Amgen initiated a Phase 1 study evaluating a new delivery approach for the osteoporosis drug Evenity. The study could improve convenience or broaden commercial potential, but it remains an early-stage program. Amgen Fine-Tunes Evenity Delivery
• Negative Sentiment: Valuation and analyst disagreement remain risks. Bank of America Securities maintained a Sell rating, while several previously issued targets were well below the current trading range. Insiders have also reported seven open-market sales and no purchases during the past six months, which may weigh on sentiment.

Insider Transactions at Amgen

In related news, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 in the last 90 days. 0.85% of the stock is currently owned by company insiders.

Amgen Stock Up 3.2%

AMGN stock traded up $13.27 during midday trading on Wednesday, reaching $426.11. 3,078,575 shares of the company’s stock traded hands, compared to its average volume of 2,749,854. The company has a market cap of $230.37 billion, a price-to-earnings ratio of 26.48, a P/E/G ratio of 3.01 and a beta of 0.41. The firm’s fifty day moving average price is $414.16 and its 200-day moving average price is $373.24. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 52 week low of $288.00 and a 52 week high of $447.03.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period last year, the firm earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Friday, August 21st. Amgen’s dividend payout ratio is currently 62.65%.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.